Delving into the Latest Updates on Bristol-Myers Squibb SRL with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Otorhinolaryngologic Diseases

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2
Hemic and Lymphatic Diseases	2
Endocrinology and Metabolic Disease	1
Immune System Diseases	1
Infectious Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

PBPs(Bacterial penicillin-binding protein)	1
DNA	1

这是一项非干预性上市后监测研究，旨在向中国FDA（CFDA）履行一项批准后承诺（PAC）。主要研究以盐酸达拉他韦（DCV）为基础的治疗方案在常规临床应用中用于慢性丙肝（CHC）患者的预期和非预期药物相关不良事件（AE）及严重不良事件（SAE）的发生率。

[Translation]

This is a non-interventional post-marketing surveillance study designed to fulfill a post-approval commitment (PAC) to the China FDA (CFDA). The study is focused on the incidence of expected and unexpected drug-related adverse events (AEs) and serious adverse events (SAEs) of daclatasvir hydrochloride (DCV)-based regimens in routine clinical use in patients with chronic hepatitis C (CHC).

Start Date08 May 2018

Sponsor / Collaborator

Bristol-Myers Squibb (China) Investment Co. Ltd.

[+3]

NCT03542461 / Active, not recruitingPhase 3IIT

An Open-label, Randomized Phase III Study of Early Switch Maintenance vs DElayed Second-line Nivolumab in Advanced Stage Squamous Non Small-cell Lung Cancer (NSCLC) Patients After Standard First-line Platinum-based Chemotherapy - EDEN Trial

The study's hypothesis is that using Nivolumab as early switch maintenance, after 4-6 cycles of standard first-line chemotherapy, might improve survival in patients with advanced stage squamous NSCLC.

Start Date25 Sep 2017

Sponsor / Collaborator

Bristol-Myers Squibb SRL

[+3]

CTR20132365 / RecruitingPhase 2

400mg伊马替尼治疗3个月未获得最佳响应的慢粒白血病患者中达沙替尼vs伊马替尼治疗的开放标记、随机2B期研究

[Translation] An open-label, randomized, phase 2B study of dasatinib versus imatinib in patients with chronic myeloid leukemia who have not achieved a best response to 400 mg imatinib for 3 months

本研究的主要目的是比较一线伊马替尼治疗未获得最佳反应（BCR-ABL＞10%IS），在第3个月被随机分配接受达沙替尼100mgQD或任何剂量伊马替尼治疗的患者中，一线伊马替尼第1天治疗后的12个月MMR率.

[Translation]

The primary objective of this study was to compare the 12-month MMR rate after first-line imatinib day 1 in patients who did not achieve optimal response to first-line imatinib (BCR-ABL > 10% IS) and were randomized to receive dasatinib 100 mg QD or any dose of imatinib at month 3.

Start Date08 May 2014

Sponsor / Collaborator

Bristol-Myers Squibb (China) Investment Co. Ltd.

[+3]

100 Clinical Results associated with Bristol-Myers Squibb SRL

Login to view more data

0 Patents (Medical) associated with Bristol-Myers Squibb SRL

Login to view more data

1

Literatures (Medical) associated with Bristol-Myers Squibb SRL

ClinicoEconomics and Outcomes Research

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

Article

Author: Di Giambenedetto, Simona ; Restelli, Umberto ; Fabbiani, Massimiliano ; Nappi, Carmela ; Croce, Davide

100 Deals associated with Bristol-Myers Squibb SRL

Login to view more data

100 Translational Medicine associated with Bristol-Myers Squibb SRL

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

2

Login to view more data